Sofinnova Ventures has led a round of $23 million for InteKrin Therapeutics, which is pursuing therapies for diabetes and obesity. InteKrin was set up in 2005 by Amgen exec Denny Lanfear and Harvard Med professor Christos Mantzoros, M.D. The money is earmarked for the clinical development of a type 2 diabetes drug.
- see the release on the round
- read the report from the San Francisco Business Times